Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim versus placebo for thrombocytopenia in low- or intermediate-1-risk myelodysplastic syndrome
NL-OMON39254Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Romiplostim with Placebo (2 arms). Primary endpoint: Incidence of clinically significant bleeding events. Started May 2009; status: active, not recruiting.
02
Drugs
romiplostim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON39254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39254.